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Abstract
Background: A key step in the design of a randomised controlled trial (RCT) is the estimation of the number of participants
needed. By far the most common approach is to specify a target difference and then estimate the corresponding sample size;
this sample size is chosen to provide reassurance that the trial will have high statistical power to detect such a difference
between the randomised groups (at the planned statistical significance level). The sample size has many implications for
the conduct of the study, as well as carrying scientific and ethical aspects to its choice. Despite the critical role of the
target difference for the primary outcome in the design of an RCT, the manner in which it is determined has received
little attention. This article reports the protocol of the Difference ELicitation in TriAls (DELTA2) project, which will produce
guidance on the specification and reporting of the target difference for the primary outcome in a sample size
calculation for RCTs.
Methods/design: The DELTA2 project has five components: systematic literature reviews of recent methodological
developments (stage 1) and existing funder guidance (stage 2); a Delphi study (stage 3); a 2-day consensus meeting
bringing together researchers, funders and patient representatives, as well as one-off engagement sessions at relevant
stakeholder meetings (stage 4); and the preparation and dissemination of a guidance document (stage 5).
Discussion: Specification of the target difference for the primary outcome is a key component of the design of an RCT.
There is a need for better guidance for researchers and funders regarding specification and reporting of this aspect of
trial design. The aim of this project is to produce consensus based guidance for researchers and funders.
Keywords: Target difference, Clinically important difference, Sample size, Guidance, Randomised controlled trial,
Pilot study, Effect size
Background
The randomised controlled trial (RCT) is widely consid-
ered to be the gold standard for assessing comparative
clinical efficacy, effectiveness and safety, as well as pro-
viding an important vehicle to assess cost-effectiveness
[1]. RCTs are routinely used to evaluate a wide range of
interventions and have been used successfully in a
variety of health care settings. Central to the design of
an RCT is an a priori sample size calculation which
ensures that the study has a high probability of achieving
its pre-specified objectives.
A compromise is required when designing an RCT to
balance the possibility of being misled by chance when
there is no true difference between treatments (type I
error), with the risk of failing to identify a treatment differ-
ence when one treatment is truly superior to the other
(type II error) [2]. Under the conventional (sometimes re-
ferred to as Neyman-Pearson) approach, the probabilities
of these two errors are controlled by setting the signifi-
cance level (type I error) and statistical power (1 − type II
error) at appropriate levels. Once these two inputs have
been set, the sample size can be determined, given the
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magnitude of the between-group difference in the out-
come that is to be detected.
The difference between groups used to calculate a tri-
al’s sample size—that is, the ‘target difference’—is the
magnitude of difference that the RCT is designed to reli-
ably detect. It can be expressed as an absolute difference
(e.g., mean difference) or a relative difference (e.g., HR
or risk ratio), and it is also often referred to as the trial’s
effect size. The required sample size is very sensitive to
the target difference. Under the conventional approach,
halving the target difference quadruples the sample size
for a two-arm 1:1 parallel-group trial with a continuous
outcome which is assumed to be normally distributed
[2]. Appropriate sample size formulae vary, depending
upon the proposed trial design and statistical analysis,
although the overall approach is consistent. In addition
to the conventional approach, other statistical ap-
proaches (to calculating the sample size) can be used,
such as Fisherian/precision-based approaches, Bayesian
and Bayesian decision-theoretic approaches, along with
a hybrid of the Bayesian and Neyman-Pearson ap-
proaches [3–7]. However, a relatively recent review of
215 RCTs in leading medical journals identified only the
Neyman-Pearson approach in use [4].
A comprehensive methodological review conducted by
the original Difference ELicitation in TriAls (DELTA)
group [8, 9] highlighted the available methods and limi-
tations in current practice. It showed that despite there
being many different approaches available, some are
rarely used in practice [10]. Although relevant to all
types of outcomes, a substantial amount of research has
been carried out on patient-reported quality-of-life out-
comes, reflecting not only that patients may find specify-
ing an important difference more difficult than clinicians
but also the general challenge of interpreting quality-of-
life measures and the value of the patient’s perspective
[11, 12]. In practice, the target difference is often not
formally based upon these concepts and in many cases
appears, at least on the basis of trial reports, to be deter-
mined on the basis of convenience or some other infor-
mal basis [13].
Recent surveys of practice of researchers involved in
clinical trials have demonstrated that determination of
the sample size, including specification of the target
difference, is a more complex process than the trial re-
ports suggest [10]. Initial guidance has been prepared
for non-adaptive superiority two-arm parallel-group
trials which are to be analysed according to the
Neyman-Pearson approach [14]. However, this guid-
ance does not cover trials of alternative hypotheses
(i.e., equivalence/non-inferiority trials), more complex
designs (e.g., multi-arm trials) or other alternative stat-
istical approaches (Bayesian and precision-based) to
choosing the target difference and reporting the
sample size calculation. There are signs that the recent
work led by the DELTA group has begun to influence
practice through citations, presentations and anecdotal
experience [15, 16]. However, it is clear that limitations
in the scope and conception (because it was developed
primarily for researchers) of the initial DELTA guid-
ance mean that it does not fully meet the needs of fun-
ders and researchers in terms of understanding the
role of the target difference in various designs and op-
tions available to inform its choice.
Aim and objectives
The overall aim of the project is to produce updated
guidance for researchers and funders on specifying and
reporting the target difference (‘effect size’) in the sam-
ple size calculation of an RCT. The following are the
specific objectives:
1. To review existing guidance provided by funders to
researchers and scientific review panel/board members
2. To identify key methodological developments or
changes in practice which have emerged since the
comprehensive DELTA review [8, 9] was undertaken
and update the DELTA method guidance
3. To determine the scope of guidance that would aid
researchers and address funders’ needs
4. To achieve consensus on what structured guidance
for choosing the target difference (effect size) should
comprise
5. To identify future research needs
To achieve these objectives, we will systematically re-
view the methodological literature for approaches to de-
termining the target difference in RCTs which have been
published since the DELTA review was completed in
2011 (stage 1). In addition, experts will be asked about
recent methodological developments and changes in
practice (stage 2). Following this, a Delphi study involv-
ing key stakeholders will be undertaken to gather views
on the needed scope and focus of the guidance needed
(stage 3). Embedded within the Delphi study will be a 2-
day consensus workshop, which will bring together key
stakeholders (stage 4) to reach agreement on key aspects
of the structured guidance for researchers and funders
that will be prepared. Following completion of the Del-
phi study, this guidance will be reviewed, finalised and
disseminated (stage 5).
Methods/design
Overview
As noted above, we will follow a five-stage process to
meet the stated project aims and objectives:
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 Stages 1 and 2: conduct literature reviews and update
method guidance
 Stage 3: conduct Delphi process
 Stage 4: hold a 2-day workshop and one-off stakeholder
engagement sessions
 Stage 5: finalise core guidance, tailor to funding
streams and disseminate to stakeholders (researchers
and funders)
Stages 1 and 2: review of methodological developments
Summary
A review of methodological developments will be under-
taken based primarily upon an electronic search of leading
journals.
Identifying relevant literature
The primary method for identifying reports of relevant
primary and secondary research will be an electronic
search in PubMed of the titles and abstracts of papers in
leading journals in trials, health economics, methodology
and statistics (see Appendix 1 for full list of journals).
The set of chosen journals includes those where previ-
ous methodological work in this area has been published
[8, 9], supplemented by other leading journals. Informed
by the DELTA review, we will search for titles and ab-
stracts containing the key terms ‘sample size’, ‘target dif-
ference’ and ‘effect size’, as well as common methods
terms (‘important difference’). On the basis of a scoping
search, the number of titles and articles identified by this
search strategy varied from 9 to 45 per year, of which 3%
to 15% were selected for full-text assessment. The search
period will be from January 2011 (post-search period of
the DELTA review) to a date 3 months prior to the con-
sensus workshop (stage 5).
We will also review online guidance that has been pro-
vided by the relevant UK trial funding schemes run by
the National Institute for Health Research (NIHR), in-
cluding EME, Health Technology Assessment (HTA),
the Research for Patient Benefit Programme, Programme
Grants for Applied Research (PGfAR), Public Health
Research (PHR), Invention for Innovation (i4i), and
Health Services and Delivery Research; the Medical Re-
search Council (MRC) Developmental Pathway Funding
Scheme (DPFS); the Wellcome Trust (Health Challenge
Innovation Fund); and Cancer Research UK (CRUK)
(phase III clinical trial, new agent, population research).
We will also review any guidance documents relating to
sample size specification provided by the NIHR Research
Design Service (RDS). Online guidance documents will
be reviewed with individual schemed contact to provide
clarification where necessary. We will also review guidance
provided by leading international funding streams
(National Institutes of Health [NIH], Patient-Centered
Outcomes Research Institute [PCORI], Canadian Institutes
of Health Research [CIHR], National Health and Medical
Research Council [NHMRC]).
We shall augment the electronic journal search as
follows:
1. Contacting experts known to have an interest in the
field: We shall contact experts whom we know have
an interest in the methodology of sample size
calculations and specifically specifying the target
difference. A number of key figures in the literature
are collaborators on this project. In addition, we
shall also contact authors of key studies already
known to us.
2. Methods adopted by UK clinical researchers: As
described more fully below, the Delphi process
involving leading stakeholders including (UK Clinical
Research Collaboration [UKCRC]) registered clinical
trials units (CTUs) and MRC Hubs for Trials
Methodology Research (HTMR) will provide
another avenue to identifying any new methods
or methodological development in methods previously
identified.
Screening and assessing papers for inclusion and summarising
findings
Papers reporting a methodological development for spe-
cifying the target difference for a trial will be included.
Titles and abstracts will be screened independently by
two people. The full-text papers will be obtained if on
initial screening they are considered potentially relevant.
Only those papers deemed relevant after this will be in-
cluded in the review.
Selection of methods
Methodological developments will be assessed by two
reviewers and noted according to the categorisation used
in the previous review. A third (content expert) member
of the team will act as arbiter if there is disagreement at
any stage.
Reporting
Each innovation will be summarised in turn and placed
in the context of the existing guidance. An updated nar-
rative summary of the evidence for each method will be
produced accordingly as appropriate.
Stage 3: Delphi study
Summary
We will conduct a multi-round (at least two and no
more than three rounds) Delphi study with stakeholders
known to have an interest in the design of RCTs about
guidance for specifying the target difference in an RCT
sample size calculation. The Delphi study will have em-
bedded in it a 2-day consensus meeting and one-off
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stakeholder engagement sessions (stage 4; see below for
details). Findings from the first Delphi round will feed
into the 2-day consensus meeting, which in turn will in-
form the subsequent questionnaires.
Participants
Invitations will be sent to known experts (informed by the
DELTA review and stage 1) along with representatives of
key trial groups. One named individual per group (unit,
board, MRC HTMR, RDS centre, or programme; e.g., the
director, chair or senior methodologist) will be invited to
participate. Groups which will be invited to send represen-
tatives to participate will include the UKCRC network of
clinical trial units (CTUs), the MRC HTMRs, NIHR/
MRC/CRUK funding programme panels, the NIHR statis-
tics group and the NIHR RDS. They will be contacted
using publicly available contact information. These groups
represent UK centres and networks of excellence that
undertake high-quality trials research. As of 1 July 2016,
there are 48 (fully or provisionally) registered units, five
MRC HTMRs and the ten regions in the NIHR RDS in
England and the Research Design and Conduct Service in
Wales. (Analogous services do not exist for Scotland and
Northern Ireland).
To give an additional perspective, we will also the
organising committee of the NIHR statistics group, to
participate as stakeholders in the Delphi process.
Sample size
It is anticipated that around one-third of invitees will
agree to participate in the Delphi process. To achieve a
minimum of 30 participants, at least 90 invitations will
need to be sent out, though no strict maximum will be
applied to reflect the arbitrary nature of this target.
Methods
An initial invitation email will be sent to potential par-
ticipants. If they agree to participate, they will be entered
into the Bristol Online Surveys (BOS) system online,
which will then administer the separate questionnaire
rounds. A separate email will be sent to each participant
with a personalised link enabling access to the online
questionnaire and allowing completion. The DELTA2
survey rounds will be administered online using the
BOS system (University of Bristol). Participants will be
invited by email to participate in an online questionnaire
and assess the importance of potential areas to cover
topic items selected from previous research.
Content of the questionnaires
The initial round 1 questionnaire will ask for informa-
tion relating to the background of the individual in
terms of training, role and experience. Questions will be
tailored to the stakeholder groups with some questions
addressed only to specific stakeholders (e.g., more meth-
odologically focussed questions for researchers in the
area). The questionnaire will also ask about the type of
trials (e.g., in terms of phases), sample size approaches
(e.g., Bayesian, Bayesian decision-theoretic), designs (e.g.,
cluster, adaptive) and associated considerations aspects
(e.g., missing data and compliance) that should be cov-
ered by future guidance. The survey, together with
stakeholder meetings, will identify the key topic areas
and also views on scope. An opportunity to raise an add-
itional topic or to make a general comment on guidance
in this area will be provided.
The round 1 questionnaire (Additional file 1: Appendix 4)
is anticipated to take approximately 10–15 minutes to
complete. Subsequent rounds (the second and, if necessary,
third questionnaires) will be of a similar nature (some ques-
tions will be the same, whereas others will be related ques-
tions of a similar style and topic) and length (again taking
approximately 10–15 minutes to complete), and they will
include a summary of findings from the previous rounds.
As necessary, we will use a structured telephone discussion
to elicit further details (if permission is granted within the
questionnaire).
Data collection and analysis
Responses are stored securely on the BOS system and will
be downloaded to a secure file space. Analyses of findings
will be summarised both overall and by stakeholder group.
Where appropriate, an ordinal 5- or 6-point scale (e.g.,
‘Strongly disagree’ to ‘Strongly agree’) will be used, which
includes ‘neutral’ and ‘no opinion’ options where appropri-
ate. Similarly, a scale ranging from ‘none’ to ‘extensive’ will
be used to assess the degree to which an issue or type of
design needs to be covered in any future guidance. All
analyses will be descriptive in nature, and no inferential
statistical analyses are planned (i.e., no statistical hypoth-
eses will be formally tested).
Output
It is anticipated that the findings of the Delphi study will
be summarised and submitted for publication as a peer-
reviewed manuscript.
Stage 4: 2-day consensus meeting and one-off stakeholder
engagement sessions
Summary
In addition to the Delphi process, we will involve stake-
holders through one-off events as part of the consensus-
building process. The main way this will occur is through
a face-to-face 2-day consensus meeting of approximately
30 stakeholders to agree on the structure and content of
the guidance to be provided with post-meeting review and
refinement (stage 5). Additionally, we will hold one-off
engagement sessions at relevant stakeholder meetings.
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Further details pertaining to participants and content of
the 2-day consensus meeting and the one-off engagement
sessions are given below.
2-day consensus meeting
Meeting participants will be selected to cover a range of
perspectives, expertise levels and roles. Draft guidance
and recommendations for researchers and funders of
clinical trials will be developed, incorporating previous
work updated in light of the initial findings from stage 3.
The structure of the 2-day meeting will be informed by
stages 1–3 of the DELTA2 project and discussion with
stakeholders. The workshop will likely include presenta-
tions of the previous DELTA project and how this has been
updated in light of stages 1 and 2 of the DELTA2 project,
along with findings from the first round of the stage 3
Delphi study. Parallel small-group sessions will be consid-
ered to increase available time and enable more technical
topics (e.g., statistical approach and design-specific issues)
to be covered. The guidance will concisely detail the
strengths and weaknesses of each approach and will be
divided into separate guidance sections on methods, study
design-specific issues (e.g., adaptive trials) and special
topics (e.g., types of outcome and summary measure).
One-off stakeholder engagement sessions
One-off stakeholder engagement sessions will include
contributing session proposals to relevant conferences
such as the SCT and PSI, as well as holding a meeting
with the Medical Section of the Royal Statistical Society,
to enable a broader group of stakeholders to contribute
to the consensus-building process. Participants in the
one-off sessions will reflect the membership of the rele-
vant group and will be somewhat opportunistic. Content
will reflect the current stage of consensus-building and,
where relevant, findings from the Delphi process and
draft guidance.
Stage 5
Tailoring the guidance
Following the completion of stages 1–4, provisional
guidance will be drafted and circulated to the project
team and consensus meeting participants for comment
(stage 5). Once the core guidance is agreed upon, we will
approach the trial-relevant MRC/NIHR funding panels
as per stage 2 to ensure that the guidance meets each
funding programme’s needs. We will engage with the in-
dividual UK funding bodies to tailor guidance to a for-
mat that they would find most useful.
Identifying future research needs
As part of the development of the guidance and recom-
mendations, key uncertainties that remain will be
recorded, thus enabling further research to address them
to be prioritised.
Discussion
Researchers face a number of difficult decisions when
designing an RCT, including the choice of trial design,
primary outcome and sample size. The latter is driven
largely by the choice of target difference (‘effect size’),
although other aspects of sample size determination also
contribute. Existing guidance on determination of the
target difference is limited, and there has been growing
recognition of the need for greater guidance for funders
and researchers, as well as other key stakeholders, such
as patients and the respective clinical communities.
DELTA2 is seeking to produce practical and comprehen-
sive guidance which is applicable to the vast majority of
trials to bridge the gap between existing guidance and
the needs of researchers.
Appendix 1: list of journals to be reviewed, by
subject area
Trials (Trials, Clinical Trials, Contemporary Clinical Trials)
Health economics (Journal of Health Economics, Health
Economics, Value in Health, European Journal of Health
Economics, International Journal of Epidemiology, Medical
Decision Making, Pharmacoeconomics, Public Health),
Methodology (American Journal of Epidemiology,
American Journal of Public Health, BMC Medical
Research Methodology, Epidemiology, Journal of Clinical
Epidemiology, International Journal of Epidemiology)
Statistical analysis (Biometrics, Biometrika, Biostatistics,
Biometrical Journal, Journal of the Royal Statistical Society.
Series C: Applied Statistics, Statistics in Biopharmaceutical
Research, Statistics in Medicine, Statistical Methods in
Medical Research, Journal of Biopharmaceutical Statistics,
Pharmaceutical Statistics)
Appendix 2: list of funding body guidance to be
reviewed
United Kingdom: NIHR (Efficacy and Mechanism Evalu-
ation [EME], Health Technology Assessment [HTA],
Research for Patient Benefit Programme [RfPB], Programme
Grants for Applied Research [PGfAR], Public Health Re-
search [PHR], Invention for Innovation [i4i], Health Services
and Delivery Research); MRC (Developmental Pathway
Funding Scheme [DPFS], Wellcome Trust [Health Chal-
lenge Innovation Fund], Arthritis Research UK, British
Heart Foundation, Cancer Research UK [clinical research,
new agent, population research]); NIHR Research Design
Service; NIHR Statistics Group; and NHS Health Research
Authority (HRA).
United States: Food and Drug Administration, PCORI,
National Institutes of Health, and Agency for Healthcare
Research & Quality.
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Canada: Health Canada (drugs and health products)
and Canadian Institutes of Health Research (CIHR).
Other: European Commission (Horizon 2020) and
Australian Clinical Trials.
Appendix 3: sample search strategy
Sample PubMed search: (‘sample size’[TIAB] OR ‘target dif-
ference’[TIAB] OR ‘effect size’[TIAB] OR ‘important differ-
ence’[TIAB] or ‘detectable difference’[TIAB] OR ‘power
calculation’[TIAB] OR ‘value of information’[TIAB] OR
‘value of perfect information’[TIAB] OR ‘value of partial
perfect information’[TIAB] OR ‘value of sampling informa-
tion’[TIAB] OR ‘expected net gain’[TIAB]) AND ‘Trials’
[TA] AND (‘2011/01/01’[PDAT]: ‘2016/03/31’[PDAT]).
Additional file
Additional file 1: Appendix 4 Delphi online questionnaire images. See
accompanying document with the filename DELTA2_Protocol_Appendix4_
DelphiQuestionnaire_11Jul2016.pdf (PDF 108 kb)
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